Skip to main content

BIO Bio-Rad Laboratories, Inc.

Healthcare

366.16 -6.02 -1.62% Close 11/2
Since 2024-12-02 +9.9%
Open
374.79
High
377.90
Low
361.27
Prev close
372.18
Volume
211.8K
Amplitude
4.47%
P/E
45.1
P/B
1.4
Revenue YoY (TTM)
+1.4%
52W 236.73 396.23

Is Bio-Rad Laboratories, Inc. a buy? Fundamentals and valuation first

As of 2026-10-30

Momentum: Good, Risk / liquidity: Good; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Good, but TTM P/E is Expensive.
TTM P/E 45.11 81th percentile Expensive
Price / book 1.39 47th percentile Fair
Free-cash-flow yield (%) 3.55 60th percentile Good
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Neutral FCF margin, TTM is Good, but ROE, TTM is Average.
ROE, TTM (%) 3.1 48th percentile Average
Operating margin, TTM (%) 9.08 54th percentile Good
FCF margin, TTM (%) 13.64 67th percentile Good
Quality Factor Investing: A US Quality Value Backtest
Growth Neutral All 2 indicators are Average.
Revenue growth, TTM YoY (%) 1.37 39th percentile Average
Diluted EPS growth, TTM YoY (%) -29.67 42th percentile Average
Momentum Good 60-day return is Top; 240-day return is Good.
60-day return (%) 8.69 84th percentile Top
240-day return (%) 18.85 70th percentile Good
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Good 20-day dollar volume is Top; 60-day annualized volatility is Good.
20-day dollar volume 82,908,647 86th percentile Top
60-day annualized volatility (%) 27.88 31th percentile Good
Factor Investing Explained: 10 Classic Factors in US Stocks

Bio-Rad Laboratories, Inc. (BIO) today

1 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From Bio-Rad Laboratories, Inc. to every stock like it

AI finds several complementary traits of Bio-Rad Laboratories, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. (BIO) peers and tracking

Watchlist

This page refreshes daily after the close. Add Bio-Rad Laboratories, Inc. to your watchlist to track signal changes on your next visit.

Bio-Rad Laboratories, Inc. (BIO) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Top-quintile 6-month momentum

Active · now 90.07%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
20 historical occurrences (since 2016-11-08)

Average forward return after Top-quintile 6-month momentum

20-day: Win 47.4%, Sample 19, Median -0.02%, Excess -1.56%, Beat mkt rate 47.4%

60-day: Win 55.6%, Sample 18, Median +4.56%, Excess -1.97%, Beat mkt rate 44.4%

120-day: Win 50%, Sample 18, Median +3.73%, Excess -1.29%, Beat mkt rate 55.6%

120 days after: historical avg +1.24%

20-day -1.49%
60-day +0.39%
120-day +1.24%
20-day
60-day
120-day
Win
47.4%
55.6%
50%
Sample
19
18
18
Median
-0.02%
+4.56%
+3.73%
Excess
-1.56%
-1.97%
-1.29%
Beat mkt rate
47.4%
44.4%
55.6%

Over 18 occurrences, 120-day forward avg gained 1.24%, lagged the market by 1.29 pts; win rate 50%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 408-7.2% -8% 43.9% -49.8%
20-40 107+0.6% +27.3% 68.2% -39.1%
40-60 6Insufficient data
60-80 You are here3Insufficient data
80-100 0Insufficient data

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 45.11, placing it in the 75.0 own-history percentile, inside the 60-80 bucket.

More history: Valuation × momentum analogs, Market-wide momentum baseline, Signals not active now

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation
Momentum
Cheap (own-history bottom third)
Middle
Expensive (own-history top third)
60-day momentum up
+7.9%
Win rate 76.3% Excess -4.5%
355d
Insufficient data
(4d)
Now
+1.2%
Win rate 68.3% Excess -12.8%
63d
60-day momentum down
-19.5%
Win rate 38.8% Excess -57.3%
160d
+35.7%
Win rate 100% Excess +22.5%
54d
Insufficient data
(8d)

Currently in “Expensive (own-history top third) × 60-day momentum up”: across 63 historical days, 120-day forward avg gained 1.2%, win rate 68.3%, lagged the market by 12.8%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

22 times historically; 60-day forward avg +4.25%, win rate 68.2%, beating the market by +1.77 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest

34 times historically; 60-day forward avg +4.18%, win rate 70%, beating the market by +1.29 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.